Zacks: Analysts Expect Endo International PLC (NASDAQ:ENDP) Will Post Quarterly Sales of $708.34 Million

Wall Street analysts expect that Endo International PLC (NASDAQ:ENDP) (TSE:ENL) will post sales of $708.34 million for the current quarter, Zacks Investment Research reports. Six analysts have issued estimates for Endo International’s earnings, with the highest sales estimate coming in at $728.30 million and the lowest estimate coming in at $699.80 million. Endo International posted sales of $745.47 million during the same quarter last year, which would indicate a negative year-over-year growth rate of 5%. The firm is expected to report its next earnings report on Thursday, November 14th.

On average, analysts expect that Endo International will report full year sales of $2.86 billion for the current year, with estimates ranging from $2.82 billion to $2.89 billion. For the next fiscal year, analysts forecast that the company will report sales of $2.86 billion, with estimates ranging from $2.64 billion to $2.98 billion. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow Endo International.

Endo International (NASDAQ:ENDP) (TSE:ENL) last issued its quarterly earnings results on Monday, August 5th. The company reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of $0.47 by $0.05. The firm had revenue of $699.71 million during the quarter, compared to the consensus estimate of $694.60 million. Endo International had a negative return on equity of 129.30% and a negative net margin of 19.98%. Endo International’s revenue for the quarter was down 2.1% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.76 earnings per share.

ENDP has been the topic of several research reports. Morgan Stanley set a $2.00 price objective on Endo International and gave the company a “sell” rating in a research note on Friday, August 9th. Cantor Fitzgerald cut their price objective on Endo International from $18.00 to $4.75 and set a “neutral” rating on the stock in a research note on Wednesday, June 12th. Barclays initiated coverage on Endo International in a research note on Tuesday, June 11th. They set an “equal weight” rating and a $6.00 price objective on the stock. ValuEngine cut Endo International from a “sell” rating to a “strong sell” rating in a research note on Tuesday, May 28th. Finally, Royal Bank of Canada restated a “hold” rating and set a $6.00 price objective on shares of Endo International in a research note on Thursday, August 8th. Four analysts have rated the stock with a sell rating, eleven have given a hold rating and two have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $7.89.

In related news, Director Roger H. Kimmel sold 34,951 shares of the stock in a transaction dated Monday, June 17th. The shares were sold at an average price of $3.93, for a total value of $137,357.43. Following the completion of the transaction, the director now directly owns 148,309 shares in the company, valued at approximately $582,854.37. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.50% of the stock is owned by company insiders.

Several institutional investors have recently modified their holdings of ENDP. Paloma Partners Management Co bought a new position in shares of Endo International in the 2nd quarter worth about $98,000. Meeder Asset Management Inc. grew its position in Endo International by 47.1% during the 2nd quarter. Meeder Asset Management Inc. now owns 37,887 shares of the company’s stock valued at $156,000 after purchasing an additional 12,127 shares during the last quarter. Factorial Partners LLC purchased a new stake in Endo International during the 1st quarter valued at about $193,000. Commonwealth Bank of Australia grew its position in Endo International by 41.6% during the 2nd quarter. Commonwealth Bank of Australia now owns 66,400 shares of the company’s stock valued at $273,000 after purchasing an additional 19,500 shares during the last quarter. Finally, Hunter Associates Investment Management LLC grew its position in Endo International by 37.4% during the 2nd quarter. Hunter Associates Investment Management LLC now owns 94,075 shares of the company’s stock valued at $388,000 after purchasing an additional 25,625 shares during the last quarter. Institutional investors own 95.80% of the company’s stock.

NASDAQ ENDP traded down $0.04 on Tuesday, hitting $3.92. 167,274 shares of the stock traded hands, compared to its average volume of 9,744,917. The stock has a 50-day moving average of $2.77 and a 200 day moving average of $5.64. Endo International has a twelve month low of $1.97 and a twelve month high of $18.50. The company has a market capitalization of $929.40 million, a P/E ratio of 1.36 and a beta of 1.23.

About Endo International

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.

See Also: Monthly Dividend Stocks

Get a free copy of the Zacks research report on Endo International (ENDP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.